 C-Peptide
"C-Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
| Descriptor ID |
D002096
|
| MeSH Number(s) |
D06.472.699.587.200.500.250 D12.644.548.586.200.500.250
|
| Concept/Terms |
C-Peptide- C-Peptide
- C Peptide
- Connecting Peptide
- Proinsulin C-Peptide
- Proinsulin C Peptide
- C-Peptide, Proinsulin
- C Peptide, Proinsulin
|
Below are MeSH descriptors whose meaning is more general than "C-Peptide".
Below are MeSH descriptors whose meaning is more specific than "C-Peptide".
This graph shows the total number of publications written about "C-Peptide" by people in this website by year, and whether "C-Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 2 | 1 | 3 | | 2009 | 0 | 3 | 3 | | 2010 | 2 | 4 | 6 | | 2011 | 0 | 1 | 1 | | 2012 | 3 | 2 | 5 | | 2013 | 4 | 5 | 9 | | 2014 | 2 | 3 | 5 | | 2015 | 1 | 4 | 5 | | 2016 | 1 | 7 | 8 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 6 | 9 | | 2019 | 0 | 3 | 3 | | 2020 | 2 | 2 | 4 | | 2021 | 2 | 7 | 9 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 8 | 8 | | 2024 | 2 | 3 | 5 | | 2025 | 3 | 2 | 5 | | 2026 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "C-Peptide" by people in Profiles.
-
Weber D, Modeste J, Peeling S, Foster TP, Bruggeman BS, Jacobsen LM, Schatz DA, Haller MJ. Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR). Diabetes Care. 2026 07 01; 49(7):1258-1261.
-
Wright EE, Low Wang CC, Novak LM, Shubrook JH. Misclassification of type 1 diabetes as type 2 diabetes in adults: practical guidance for screening and diagnosis for primary care providers. Postgrad Med. 2026 May; 138(4):396-407.
-
Dobbs TJ, Pyle L, Moore JM, Garrish J, Behn CD, Weissenkampen D, Baumgartner AD, Gross S, Schutte G, Birznieks C, Melena I, Remmers L, Driscoll L, Cree MG, Kelsey MM, Shah AS, Inge TH, Bjornstad P, Nadeau KJ. Impact of Vertical Sleeve Gastrectomy in Youth-Onset Type 2 Diabetes: Changes in Glycemia, Insulin Sensitivity, and Secretion. Obesity (Silver Spring). 2026 Jun; 34 Suppl 1:121-133.
-
Kahn SE, Tripputi M, Lachin JM, Balasubramanyam A, Banerji MA, Barzilay J, Cohen RM, Garvey WT, Gramzinski MR, Rasouli N, Rhee M, Seegmiller JC, Singh V, Sivitz WI, Steffes MW, Utzschneider K, DeFronzo RA. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026 Feb 01; 49(2):325-334.
-
Triolo TM, Sosenko JM, Cuthbertson D, Oram RA, Parikh HM, Steck AK, Sims EK, Jacobsen LM, Nathan B, Templeman EL, Onengut-Gumuscu S, Evans-Molina C, Rich SS, Atkinson MA, Redondo MJ. Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression. Diabetes. 2026 01 20; 75(2):389-397.
-
Karakus KE, Chesshir L, Walker S, Baschal EE, McDaniel KA, Triolo TM, Steck AK, Frohnert BI, Gottlieb PA, Michels AW, Simmons KM. Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes. Diabetologia. 2026 May; 69(5):1164-1175.
-
Groegler J, Mangold K, Nicholson K, Dang M, Wenzlau J, Beard KS, Hohenstein A, Powell R, Baker R, Haskins K, Matsuda J, Delong T. Strategic Reduction of Hybrid Insulin Peptide Formation Significantly Delays Diabetes Onset in NOD Mice. Diabetes. 2026 01 01; 75(1):115-123.
-
Neyman A, DiMeglio LA, Bauza C, Buckingham B, Clements MA, Forlenza GP, Sherr JL, Kanapka L, Beck RW, Kollman C, Beasley S, Cobry E, Norlander L, McDonough R, Van Name M, Moran A. Associations of CGM Metrics With Stimulated C-Peptide Measures in Youth With Recent-Onset Type 1 Diabetes. Diabetes Care. 2025 Aug 01; 48(8):1395-1399.
-
Hohenstein AC, Gallegos JB, Dang M, Groegler J, Broncucia H, Tensun FA, Waugh K, Dong F, James EA, Speake C, Steck AK, Rewers MJ, Gottlieb PA, Haskins K, Delong T, Baker RL. Novel T-Cell Reactivities to Hybrid Insulin Peptides in Islet Autoantibody-Positive At-Risk Individuals. Diabetes. 2025 Jun 01; 74(6):933-942.
-
Ferrat LA, Templeman EL, Steck AK, Parikh HM, You L, Onengut-Gumuscu S, Gottlieb PA, Triolo TM, Rich SS, Krischer J, McQueen RB, Oram RA, Redondo MJ. Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter. Diabetologia. 2025 Aug; 68(8):1709-1720.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|